Center for Clinical and Translational Sciences (CCTS)

临床和转化科学中心 (CCTS)

• 批准号: 10707570
• 负责人: DANIEL D KARP
• 金额: $ 7.15万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-24 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10707570
• 关键词: Acceleration; Address; American; Area; Award; Basic Science; Biomedical Research; Cancer Center; Childhood; Chronic lung disease; Clinical Research; Clinical Sciences; Clinical Trials; Clinical and Translational Science Awards; Collaborations; Communities; Community Health; Conduct Clinical Trials; Country; Data; Doctor of Medicine; Education; Elderly; Environment; First Independent Research Support and Transition Awards; Fostering; Goals; Health; Health Sciences; Healthcare; Hispanic; Hospitals; Individual; Informatics; Institute of Medicine (U.S.); Institution; Institutional Review Boards; Knowledge; Learning; Lesbian Gay Bisexual Transgender Queer; Malignant Neoplasms; Medical; Medical Faculty; Medical Staff; Medical center; Medicine; Methodist Church; Methods; Mexican Americans; Multi-Institutional Clinical Trial; National Center for Advancing Translational Sciences; Patients; Physicians; Population; Population Heterogeneity; Process; Reporting; Research; Research Contracts; Research Personnel; Resources; Rice; Rural; Rural Health; Schools; Science; Services; Site; Solid; South Texas; Texas; Training; Translational Research; Translations; Tuberculosis; Universities; Work; Workforce Development; base; bench to bedside; biobank; cancer care; cancer clinical trial; clinical care; clinical center; clinical data warehouse; college; community engagement; computer science; economic disparity; health training; improved; innovation; inter-institutional; multidisciplinary; next generation; novel; outreach; patient registry; population based; programs; skills; translational pipeline; translational scientist

Contact PD/PI: McPherson, David D. In the first awarded CTSA class, the Center for Clinical and Translational Sciences (CCTS) formed the first multiple-institution CTSA, with The University of Texas Health Science Center at Houston (UTHSC-H) and The University of Texas M. D. Anderson Cancer Center (UT MDACC). Since its inception the CCTS has been achieving the primary goal of the Clinical and Translational Sciences Award (CTSA) program: to accelerate research to transform healthcare and train the next generation of translational scientists. Our initial proposal was about bringing individuals and resources together, educating investigators, and building teams. In our 2011 renewal we described our Lowering-The-Barriers program, which focused on removing a large number of impediments through initiatives such as IRB reciprocity, standard research contracts and subcontracts, clinical data warehouses, patient registries, and biobanks. Our efforts have been successful and aligned with the national CTSA program. In this cycle, we bring in 3 new partner institutions to broaden and diversify our CTSA: The University of Texas Health Science Center at Tyler (northeast Texas, rural, economically disadvantaged), Rice University (with strengths in computer science, education, and team science), and The University of Texas Rio Grande Valley (south Texas, education and physician resources to help our nearby Brownsville Clinical Research Unit perform clinical trials). Together we will effect 5 strategic goals: Strategic Goal 1: To provide our investigators, staff, trainees, and scholars with the skills and knowledge necessary to advance discoveries and their translation in the new environment of clinical and translational research (Workforce Development). Strategic Goal 2: To collaborate with all of our stakeholders in a mutually beneficial way to advance translation by furthering engagement and team science (Collaboration/Engagement). Strategic Goal 3: To integrate pediatric and geriatric patients, Hispanic patients with cancer, and the LGBTQ+ community into the full spectrum of clinical and translational research (Integration). Strategic Goal 4: To advance translational science by providing novel processes, increasing efficiency, and streamlining research (Methods/Processes). Strategic Goal 5. To create and apply innovative informatics solutions to advance translational research, train the CTSA workforce, disseminate best practices, engage communities and integrate clinical and basic research data (Informatics). Page 373 Project Summary/Abstract Contact PD/PI: McPherson, David D. The CCTS will support bidirectional translational research, moving discoveries from the bench to the bedside, by training a capable workforce using our unique multidisciplinary translational teams and innovative educational programs. Our hub will serve to foster high-quality clinical research, develop best practices in team-based translations, participate in inter-institutional data-sharing, and function as an efficient site for multi- site clinical trials in our large, diverse populations. The CCTS, through its novel programs and resources, will remain an important contributor to achieving the goals of the national consortium. Page 374

联系PD/PI：麦克弗森，大卫D. 在第一次授予CTSA类，临床和转化科学中心（CCTS）形成了第一个 多机构CTSA，与德克萨斯大学休斯顿健康科学中心（UTHSC-H）和 德克萨斯大学M. D.安德森癌症中心（UT MDACC）。自成立以来，CCTS一直 实现临床和转化科学奖（CTSA）计划的主要目标：加速 研究，以改变医疗保健和培养下一代的翻译科学家。我们最初的建议 是将个人和资源聚集在一起，教育调查人员，建立团队。在我们 2011年更新，我们描述了我们的降低障碍计划，该计划侧重于消除大量的 通过IRB互惠、标准研究合同和分包合同、临床研究合同等举措， 数据仓库、患者登记处和生物库。我们的努力取得了成功，并与 国家CTSA计划。在这个周期中，我们引入了3个新的合作伙伴机构，以扩大和多样化我们的 位于泰勒的德克萨斯大学健康科学中心（德克萨斯州东北部，农村，经济 弱势），莱斯大学（在计算机科学，教育和团队科学的优势）， 和德克萨斯大学格兰德河谷（德克萨斯州南部，教育和医生资源， 帮助我们附近的布朗斯维尔临床研究单位进行临床试验）。我们一起努力5 战略目标：战略目标1：为我们的研究人员、工作人员、学员和学者提供 在新的环境中推进发现及其翻译所需的技能和知识， 临床和转化研究（劳动力发展）。战略目标2：与所有人合作 我们的利益相关者以互利的方式通过进一步参与和 团队科学（协作/参与）。战略目标3：将儿科和老年科 患者，西班牙裔癌症患者和LGBTQ+社区进入全方位的临床 转化研究（translational research）。战略目标4：推进转化科学 提供新的过程，提高效率，并简化研究（方法/过程）。 战略目标5。创建和应用创新的信息学解决方案，以推进翻译 研究，培训CTSA劳动力，传播最佳实践，参与社区和整合 临床和基础研究数据（信息学）。 第373页 项目总结/摘要 联系PD/PI：麦克弗森，大卫D. CCTS将支持双向转化研究，将发现从实验室转移到床边， 通过使用我们独特的多学科翻译团队和创新技术， 教育项目。我们的中心将致力于促进高质量的临床研究， 以团队为基础的翻译，参与机构间的数据共享，并作为一个高效的网站， 在我们庞大的、多样化的人群中进行临床试验。CCTS将通过其新颖的计划和资源， 仍然是实现国家联合会目标的重要贡献者。 第374页

项目成果

Hypoxia-inducible factor-dependent induction of myeloid-derived netrin-1 attenuates natural killer cell infiltration during endotoxin-induced lung injury.

• DOI: 10.1096/fj.202002407r
• 发表时间: 2021-04
• 期刊: FASEB journal : official publication of the Federation of American Societies for Experimental Biology
• 作者: Berg NK;Li J;Kim B;Mills T;Pei G;Zhao Z;Li X;Zhang X;Ruan W;Eltzschig HK;Yuan X
• 通讯作者: Yuan X

The current state of prenatal detection of genetic conditions in congenital heart defects.

• DOI: 10.21037/tp-20-315
• 发表时间: 2021-08
• 期刊: Translational pediatrics
• 影响因子: 2
• 作者: Findley TO;Northrup H
• 通讯作者: Northrup H

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.

• DOI: 10.1007/s10637-021-01119-0
• 发表时间: 2021-10
• 期刊: Investigational new drugs
• 影响因子: 3.4
• 作者: Thein KZ;Piha-Paul SA;Tsimberidou A;Karp DD;Janku F;Zarifa A;Shah J;Milton DR;Bean S;McQuinn L;Gong J;Colen R;Carter BW;Subbiah V;Ogbonna DC;Pant S;Meric-Bernstam F;Naing A
• 通讯作者: Naing A

Exception from informed consent in the era of social media: The SEGA stroke trial experience.

• DOI: 10.4103/bc.bc_44_21
• 发表时间: 2021-10
• 期刊: Brain circulation
• 影响因子: 1.9
• 作者: Inam ME;Sanzgiri A;Lekka E;Sheth SA;Barreto AD;Savitz SI;Artime C;Pedroza C;Engstrom A;Sheriff FG;Ambrocik A;Chen PR
• 通讯作者: Chen PR

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.

• DOI: 10.1038/s41698-021-00159-2
• 发表时间: 2021-03-19
• 期刊: NPJ precision oncology
• 影响因子: 7.9
• 作者: Tsimberidou AM;Hong DS;Fu S;Karp DD;Piha-Paul S;Kies MS;Ravi V;Subbiah V;Patel SM;Tu SM;Janku F;Heymach J;Johnson A;Cartwright C;Zhao L;Zhang J;Berry DA;Vining DJ;Futreal A;Miller VA;Meric-Bernstam F
• 通讯作者: Meric-Bernstam F